| Literature DB >> 31023523 |
Diego A Espinoza1, Xing Fan2, Di Yang3, Stefan F Cordes2, Lauren L Truitt2, Katherine R Calvo2, Idalia M Yabe2, Selami Demirci4, Kristin J Hope5, So Gun Hong2, Allen Krouse2, Mark Metzger2, Aylin Bonifacino2, Rong Lu6, Naoya Uchida4, John F Tisdale4, Xiaolin Wu7, Suk See DeRavin8, Harry L Malech8, Robert E Donahue2, Chuanfeng Wu9, Cynthia E Dunbar10.
Abstract
Lentiviral vectors (LVs) are used for delivery of genes into hematopoietic stem and progenitor cells (HSPCs) in clinical trials worldwide. LVs, in contrast to retroviral vectors, are not associated with insertion site-associated malignant clonal expansions and, thus, are considered safer. Here, however, we present a case of markedly abnormal dysplastic clonal hematopoiesis affecting the erythroid, myeloid, and megakaryocytic lineages in a rhesus macaque transplanted with HSPCs that were transduced with a LV containing a strong retroviral murine stem cell virus (MSCV) constitutive promoter-enhancer in the LTR. Nine insertions were mapped in the abnormal clone, resulting in overexpression and aberrant splicing of several genes of interest, including the cytokine stem cell factor and the transcription factor PLAG1. This case represents the first clear link between lentiviral insertion-induced clonal expansion and a clinically abnormal transformed phenotype following transduction of normal primate or human HSPCs, which is concerning, and suggests that strong constitutive promoters should not be included in LVs. Published by Elsevier Inc.Entities:
Keywords: gene therapy; genotoxicity; lentiviral vector; non-human primate
Mesh:
Substances:
Year: 2019 PMID: 31023523 PMCID: PMC6554657 DOI: 10.1016/j.ymthe.2019.04.003
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454